Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS) by unknown
Osborne et al. BMC Cancer  (2015) 15:280 
DOI 10.1186/s12885-015-1261-6RESEARCH ARTICLE Open AccessImproving the assessment of quality of life in the
clinical care of myeloma patients: the
development and validation of the Myeloma
Patient Outcome Scale (MyPOS)
Thomas R Osborne1*, Christina Ramsenthaler1, Stephen A Schey2, Richard J Siegert1,3, Polly M Edmonds1,4
and Irene J Higginson1Abstract
Background: Multiple myeloma is an incurable cancer with a rising incidence globally. Less toxic treatments are
increasingly available, so patients are living longer and treatment decisions are increasingly guided by QOL
concerns. There is no QOL assessment tool designed specifically for use in the clinical care of people with
myeloma. This study aimed to develop and test the psychometric properties of a new myeloma-specific QOL
questionnaire designed specifically for use in the clinical setting – the MyPOS.
Methods: The MyPOS was developed using findings from a previously reported literature review and qualitative
study. The prototype MyPOS was pretested using cognitive interviews in a purposive sample of myeloma patients
and refined prior to field testing. The psychometric properties of the MyPOS were evaluated in a multi-centre, cross
sectional survey of myeloma patients recruited from 14 hospital trusts across England.
Results: The prototype MyPOS contained 33 structured and open questions. These were refined using cognitive
interviews with 12 patients, and the final MyPOS contained 30 items taken forward for field-testing. The cross-sectional
survey recruited 380 patients for the MyPOS validation. Mean time to complete was 7 minutes 19 seconds with 0.58%
missing MyPOS items overall. Internal consistency was high (α = 0.89). Factor analysis confirmed three subscales:
Symptoms & Function; Emotional Response and Healthcare Support. MyPOS total scores were higher (worse QOL)
in those with active disease compared to those in the stable or plateau phase (F = 11.89, p < 0.001) and were worse
in those currently receiving chemotherapy (t = 3.42, p = 0.001). Scores in the Symptoms & Function subscale were
higher (worse QOL) in those with worse ECOG performance status (F = 31.33, p < 0.001). Good convergent and
discriminant validity were demonstrated.
Conclusions: The MyPOS is the first myeloma-specific QOL questionnaire designed specifically for use in the
clinical setting. The MyPOS is based on qualitative enquiry and the issues most important to patients. It is a brief,
comprehensive and acceptable tool that is reliable and valid on psychometric testing. The MyPOS can now be
used to support clinical decision making in the routine care of myeloma patients.
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Multiple myeloma is a malignant proliferation of plasma
cells with over 114,000 new cases globally in 2012 [1] and
an increasing incidence worldwide [2]. Myeloma causes
destruction of the bones, bone marrow failure and renal
failure, leading to impairments in physical, psychological
and social domains of quality of life (QOL) [3-5]. Myeloma
remains incurable, but median survival has increased from
24–32 months in 1992 to 68 months in 2005 due to in-
creased availability of less toxic drugs [6]. Patients are now
living longer with the complications of their illness, so clinical
decision-making is increasingly driven by QOL concerns.
It has been recommended that QOL assessment should
form part of the routine care of myeloma patients [3,4,7].
A systematic literature review identified 13 QOL tools
developed or validated for use in people with myeloma
[8]. The review identified no tool designed specifically for
clinical use, and only one disease-specific questionnaire:
the European Organisation for Research and Treatment of
Cancer core cancer questionnaire (EORTC-QLQ-C30)
with its myeloma-specific module (MY20) [9-11]. Subse-
quent to the literature review, one further myeloma-specific
questionnaire has been described: the Functional Assess-
ment of Cancer Therapy – Multiple Myeloma (FACT-MM)
[12]. The literature review revealed a paucity of studies to
fully characterise the meaning of QOL from the perspective
of myeloma patients, and concluded that the best existing
QOL questionnaires may not capture all the issues import-
ant to QOL [8]. Therefore, a detailed qualitative study has
subsequently explored the meaning of QOL from the per-
spective of people with myeloma, obtained views on a range
of existing QOL questionnaires and reported a theoretical
model of QOL in myeloma [13]. This model further
highlighted that existing questionnaires do not capture all
the issues, for example by not including items on health
service factors and sexual function that are important to
patients. The model suggested that the presence or absence
of physical symptoms per se was not the most important
determinant of QOL, but rather the impact of symptoms
on other domains such as activities, participation, and emo-
tional wellbeing. Most existing QOL questionnaires ask
only about symptom status [8] and so may not capture all
that is important to QOL.
These findings were used to develop the Myeloma Patient
Outcome Scale (MyPOS) – a new QOL assessment tool
designed for use within the clinical care of myeloma pa-
tients. The aim of the present article is to describe the




The development of the MyPOS was overseen by the
MyPOS steering group, comprising experts from thefields of haematology, palliative care, psychology and
psychometrics. Initially the steering group oversaw the
development of a prototype MyPOS. The prototype
questionnaire was pretested using cognitive interviews in
a purposive sample of myeloma patients with subsequent
refinements prior to field testing. Finally, the psychomet-
ric properties of the MyPOS were evaluated in a multi-
centre, cross sectional survey of myeloma patients re-
cruited from 14 hospital trusts across England. This
study forms part of a wider programme of work to im-
prove the assessment of QOL in the clinical care of mye-
loma patients.
Prototype MyPOS development
It was considered preferable to modify an existing ques-
tionnaire rather than design a completely new tool, to
take advantage of existing development work and rele-
vant items that had been field-tested and used in clinical
practice. The literature review had identified that the
EORTC-QLQ-C30 and MY20 had undergone the most
extensive psychometric validation in myeloma patients,
but that these tools were designed for use in research
and are predominantly health status questionnaires that
may not be well suited to clinical use [8]. To align better
with the findings of the earlier qualitative study [13], the
steering group sought to adapt a tool that required re-
spondents to consider the impact of physical symptoms
on wider experience, rather than just symptom status.
There was no suitable candidate identified in the system-
atic review, so the steering group chose to adapt an al-
ternative tool – the Palliative Care Outcome Scale (POS)
with its accompanying symptoms scale (POS-S) [14].
The POS was chosen because it was designed as a clin-
ical tool and is suitable for use in any chronic illness,
with many issues and themes applicable to myeloma.
Importantly, the response options used in the POS-S ask
the respondent to consider the impact of physical symp-
toms on ‘activities and concentration’, rather than just
symptom status.
Content validity of the MyPOS was ensured by basing
the items on the issues most important to patients. The
earlier qualitative study and theoretical model identified
80 issues important to QOL [13]. These were refined
into a 33-item prototype MyPOS using a combination of
structured and open questions. Physical symptoms were
only included as structured items if raised by at least 2
participants in the qualitative interviews. If raised by
only one participant, symptoms were not included as
structured items, with open questions used to capture
any less commonly occurring symptoms.
The layout and length of the prototype MyPOS were
based on the preferences of myeloma patients and clin-
ical staff, also identified in the earlier qualitative work:
the target length was no more than 2 A4 pages; items
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to reduce the amount of reading for respondents and
allow information on completed questionnaires to be
more easily assimilated by clinical staff; and the ques-
tionnaire contained a mixture of structured and open
questions to give respondents an individualised voice to




Participants for the cognitive interviews were recruited
from inpatient and outpatient settings at King’s College
Hospital NHS Foundation Trust, which provides tertiary
haemato-oncology services to London and south-east
England and contains the largest bone marrow trans-
plant centre in Europe. Inclusion criteria were those
18 years or older; a confirmed histological diagnosis of
multiple myeloma; being aware of the diagnosis; and
capacity to give written informed consent. Exclusion cri-
teria were those too unwell, symptomatic or distressed
to participate (as judged by the clinical team); severe
neutropenia where contact with researcher may pose a
risk; and unable to understand written and spoken
English.
Participants were purposively sampled by gender, age
(<65 or ≥65), Eastern Co-operative Oncology Group
(ECOG) performance status (0–2 or 3–4) and disease
phase (newly diagnosed, plateau, or relapsed [15]). Pur-
posive sampling was used to achieve maximum variation
across key characteristics thought to potentially influ-
ence participants’ views and ability to understand the
MyPOS items. The interviews were conducted in rounds
of 6, after which recruitment was paused, interviews
analysed and MyPOS refined prior to the next round 6
interviews. The number of interviews was not fixed at
the start, but recruitment was continued until no further
cognitive testing was required. There is no accepted best
practice for the number of interviews required [16], but
it has been reported that 7–10 interviews are generally
sufficient [17].
Procedure
Cognitive interviews were used to explore the cognitive
processes employed by respondents as they completed
the prototype MyPOS. The interviews included a com-
bination of think-aloud and verbal-probing techniques
to evaluate each item [16,18]. Participants completed the
prototype MyPOS and were asked to report what they
were thinking as they answered each item (think-aloud).
In practice, many participants required some direct
questioning from the interviewer to clarify the issues of
interest (verbal-probing). The interviewer probes were
standardised using an interview topic guide based on thefour-stage model of question response proposed by
Tourangeau: comprehension, retrieval, judgement and
response [19]. Specific probes were developed for each
of these stages, adapted from examples proposed else-
where [20] with additional questions to assess accept-
ability of items. The cognitive probes used are shown in
Additional file 1: Table S1.
Interviews took place in a private room with only the
interviewer and participant present to reduce bias in the
participants’ responses. Interviews were audio recorded
and conducted by a single researcher (TRO) who has a
background as a medical doctor in both haemato-oncology
and palliative medicine.
Analysis
Interviews were analysed directly from audio recordings
without transcription [21]. Data were extracted into ta-
bles constructed with participant numbers across the
top and questionnaire items down the left hand column.
For each item, the table contained a row for each stage
of question response (comprehension, retrieval, judge-
ment, response), with additional rows for acceptability
and other comments. Once the table had been populated
analysis could take place ‘item-by-item’ where all views
about each item could be considered in aggregate. Data
were extracted and analysed for all interviews by TRO.
For each round of 6 interviews a second researcher (CR)
double-extracted a single interview (randomly selected)
to check for consistency. Discrepancies were resolved by
consensus. After the completion of each round of 6 in-
terviews, any necessary refinements were made to the
MyPOS and then 6 further interviews carried out. This
was repeated until no further modifications were needed




Participants for the cross sectional survey were recruited
from outpatient clinics and inpatient wards at 14 hos-
pital trusts across England, with King’s College Hospital
NHS Foundation Trust acting as lead site. The collabor-
ating trusts included a mixture of tertiary and district
general hospitals to ensure the MyPOS was tested in a
range of settings (see Acknowledgments full list of col-
laborators). Inclusion and exclusion criteria were the
same as those used for the cognitive interviews. The sur-
vey recruited consecutive patients whereby all available
myeloma patients were screened for eligibility at every
outpatient clinic or ward where recruitment was active.
All eligible patients were asked if they would participate
in the study. All non-participants (those who were ineli-
gible and those who declined) were asked for consent to
record limited demographic and treatment details in
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recruitment target for the cross sectional survey was es-
timated based on the number of MyPOS items. Pub-
lished estimates of the required participant to item ratio
for psychometric analysis vary from 10:1 [22] to 2:1 [23].
The final MyPOS contained 27 items for psychometric
evaluation so a sample of 350 was sought as a conserva-
tive estimate with an allowance for missing data.
Procedure
Demographic and clinical characteristics were recorded
by research staff at the time of consent. Participants
were given the option of completing the questionnaire
booklet at the time of consent or taking it home and
returning by post. The questionnaire booklet contained
the MyPOS alongside the EORTC-QLQ-C30 and MY20
for validation purposes. These questionnaires were
chosen as they have undergone the most extensive psy-
chometric validation in myeloma patients [8]. The
EORTC-QLQ-C30 has 30 items broken into 5 function
scales (Physical, Role, Cognitive, Emotional, and Social
Function); 3 symptom scales (Fatigue, Pain, and Nausea/
Vomiting); a Global Health Status/QOL scale; and 6 sin-
gle items (Constipation, Diarrhoea, Insomnia, Dyspnoea,
Appetite Loss, and Financial Difficulties). Higher scores
for function and global scales represent better QOL,
whereas higher scores for symptom scales and single
items represent worse QOL. The MY20 has 20 items
broken into 3 subscales (Disease Symptoms, Side Effects
of Treatment, and Future Perspective), and a single item
for Body Image. The Future Perspective scale includes
worry about death, worry about health in the future, and
thinking about the illness. Higher scores for Disease
Symptoms and Side Effects of Treatment scales repre-
sent worse QOL, whereas higher scores for Future Per-
spective and Body Image represent better QOL.
Analysis
All demographic and questionnaire data were double en-
tered from paper booklets into electronic databases by
two separate research staff. The two resulting databases
were compared and discrepancies resolved by referring
back to source data.
Descriptive statistics were used to describe the sample
and the range and distribution of scores for individual
MyPOS items and identified subscales. The differences
between participants and non-participants were explored
in terms of gender, age (dichotomised to <65 and ≥65),
phase of disease (newly diagnosed/stable or plateau/
relapsed or progressive), and treatment status (on/off
treatment).
Acceptability was assessed by computing the propor-
tion of missing responses per item, per subscale and
overall, and by measuring time taken to complete theMyPOS in a subsample of 70 participants recruited at
the lead site.
Structural validity was established using exploratory
factor analysis to identify underlying subscales. The prin-
cipal component model with Promax rotation was used.
Choice of oblique (Promax) rotation was based on the
theoretical model of QOL in myeloma which indicated
that any potential factors might be correlated, due to the
inter-relatedness of emotional issues, symptoms, activ-
ities, participation and support factors [13]. Factorability
of the matrix was assessed by item intercorrelations
(cut-off: <.30 [24]), Barlett’s test of sphericity [25] and
the Kaiser-Meyer-Olkin test of sample adequacy [26,27].
The number of factors was determined by using three
methods: The Kaiser criterion (eigenvalues > 1); scree
plot [28]; and Velicer’s Minimum Average Partial (MAP)
test [29]. The latter method has been suggested as more
robust than the Kaiser criterion or scree plot, preventing
over- or underestimation of the number of factors [30].
The resulting pattern matrix was checked for parsimony
of factors. Items loading on more than one factor or
with small loadings were discussed in the steering group
and kept in the model if they were felt to be important
on clinical grounds.
Reliability was estimated using Cronbach’s α for
MyPOS total scores and any identified subscales. An α-
coefficient in the range 0.7-0.9 is considered desirable to
indicate good internal consistency without redundancy
of items [31-33].
Construct validity was tested using the known-group
comparison method [31]. It was hypothesised that (i)
MyPOS scores would be higher (worse QOL) in those
with active disease (newly diagnosed or relapsed) com-
pared to those in the stable or plateau phase; (ii) MyPOS
scores would be higher (worse QOL) in those currently
receiving chemotherapy compared to those who were off
treatment; and (iii) MyPOS scores would be higher
(worse QOL) in those with worse ECOG performance
status. Parametric tests were used in each case, but all
comparisons were also run using non-parametric tests
to account for non-normally distributed data (ANOVA
and Kruskal-Wallis H for phase of disease and ECOG
performance status; t-test and Mann–Whitney U for
comparison of treatment status).
Convergent and divergent validity were tested by cor-
relating subscales from the MyPOS with those from the
EORTC-QLQ-C30 and MY20. Scores from the EORTC
tools were transformed to a 0–100 scale [34] and corre-
lated with MyPOS scores using Pearson product–mo-
ment correlation coefficients with associated p values. A
strong correlation was considered to be r > 0.70 and
moderate correlation r > 0.50. The minimum relevant
correlation was considered to be r > 0.50. It was
hypothesised that (i) MyPOS total score would have
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QLQ-C30 Global Health Status/QOL scale (high MyPOS
scores represent worse QOL whereas high EORTC scores
represent better QOL); (ii) MyPOS symptom and function
items would have moderate or strong negative correlation
with EORTC-QLQ-C30 Physical Function, Role Function,
Cognitive Function and Social Function scales, and mod-
erate or strong positive correlation with MY20 Disease
Symptoms and Side Effects of Treatment scales; (iii)
MyPOS emotional wellbeing items would have moderate
or strong negative correlation with the EORTC-QLQ-C30
Emotional Function and MY20 Future Perspectives scales,
and (iv) MyPOS healthcare items would not correlate
strongly with any EORTC scale since these issues are not
captured in the EORTC questionnaires.
Statistical analyses were carried out using the Statis-
tical Package for the Social Sciences (IBM SPSS Statistics
for Windows, Version 21.0, Armonk, NY: IBM Corp). A
p-value of <0.05 was considered statistically significant
for all analyses. Missing data were excluded pairwise for
all analyses.
Ethical issues
Research Ethics Committee approval was granted by the
South East London REC-3 (ref 10/H0808/133). All pa-
tients were screened by a member of their clinical team
before being approached about participation in the
study. All participants gave written consent to take part.
Participation was voluntary and interviews or question-
naire completion took place at a time and place conveni-
ent to participants (hospital, home or other location
requested by them). Completed questionnaires were
screened for clinically important issues and where neces-
sary the participant’s consent was sought to feed such is-
sues back to the clinical team.
Results
Prototype MyPOS development
The prototype MyPOS contained 33 items including 31
structured and 2 open questions. These were composed
of 10 existing POS items (those relevant to QOL in mye-
loma) and 23 newly written items. All response options
were taken from the POS and POS-S, although the recall
period was amended from 3 days to 1 week to match the
preferences of myeloma patients and staff identified in
the previously reported qualitative interviews [13].
Prototype MyPOS items are shown in Additional file 1:
Table S2.
Cognitive interviews
Fifteen eligible patients were approached about the cog-
nitive interviews and 12 agreed to participate. Reasons
for declining were feeling too unwell (2) or no reason
given (1). Participants were recruited over a 3 monthperiod, with interviews taking place in mixture of settings
including hospital outpatients (3), hospital inpatient (3)
and the participants’ own homes (6). A balance of partici-
pants was achieved across key demographic and clinical
characteristics as shown in Additional file 1: Table S3.
After the first round of 6 interviews some items and
response options were reworded. The reworded items
were re-tested in a second round of 6 interviews. All
reworded items tested well in the second round of inter-
views, with no further refinement needed. The only
changes made after the second round were the removal
of 2 items considered to be redundant and changes to
layout. Further cognitive testing of these changes was
not deemed necessary and so recruitment was stopped
after 12 interviews. A summary of changes to the proto-
type MyPOS following the cognitive interviews is shown
in Additional file 1: Table S4.
The MyPOS taken forward for psychometric testing
contained 30 items, including 2 open questions and 1
question asking if any help was received when complet-
ing the questionnaire. 27 items were therefore included
in the psychometric analysis, each scored on a 5-point
scale from 0 (better QOL) to 4 (worse QOL). The item
about sex-life contained an additional “prefer not to an-
swer” response, which was treated as missing data for
the purposes of psychometric analysis. The complete
MyPOS taken forward for psychometric testing is shown
in Additional file 1: Table S5.
Cross sectional survey
517 patients with multiple myeloma were screened by
the clinical teams. 465 patients were eligible against the
inclusion and exclusion criteria and were approached
about the study. 401 patients consented to participate,
and completed questionnaires were received from 380
participants. Median age of participants was 69 years
(range 38–91). There were more men (60.8%) than
women (39.2%), and 181 participants (47.6%) were cur-
rently receiving treatment for their myeloma (Table 1).
There were 137 non-participants of which 52 were in-
eligible against the inclusion and exclusion criteria, 64
declined to participate and 21 consented but the com-
pleted questionnaire was not received. Reasons for ineli-
gibility were being too unwell, symptomatic or distressed
to participate (17); unable to understand written and
spoken English (13); lack of capacity to give written in-
formed consent (7); no histological confirmation of diag-
nosis (6); not yet told the diagnosis (1); and ‘other’ (8).
Reasons for declining were feeling too unwell to partici-
pate (14); feeling short of time (7); privacy concerns (4);
participating in other studies (3); other (8); and not
known (28). Comparing the 380 survey participants to
the 137 non-participants showed that the groups had
similar distributions in terms of gender, age, phase of
Table 1 Sample characteristics for cross sectional survey
(n = 380)
Setting of questionnaire completion
Hospital outpatient 266 (70%)
Hospital inpatient 18 (4.7%)
Participant’s home 93 (24.5%)










Married / partnered 275 (72.4%)
Divorcer / separated 26 (6.8%)
Widowed 45 (11.8%)
Not known 1 (0.3%)
Ethnicity
White British 326 (85.8%)









Not known 13 (3.4%)
Highest educational level
Did not finish school 27 (7.1%)
Secondary school graduate 183 (48.2%)
College / technical qualification 88 (23.2%)
University first degree 37 (9.7%)
University higher degree 21 (5.5%)
Not known 24 (6.3%)
Occupation status
Working or student 49 (12.9%)
Not working 47 (12.4%)
Retired 283 (74.5%)
Not known 1 (0.3%)
Table 1 Sample characteristics for cross sectional survey








Off treatment 199 (52.4%)
On treatment 181 (47.6%)
- High dose treatment with stem cell support 5 (1.3%)
- Chemotherapy / targeted therapy alone 141 (37.1%)
- Maintenance treatment 35 (9.2%)
Disease phase
Newly diagnosed 79 (20.8%)
Stable / plateau phase 174 (45.8%)





Light chain 65 (17.1%)
Non-secretory 4 (1.1%)
Not known 2 (0.5%)










Over 48 127 (33.4%)
Not known 22 (5.8%)
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demographics and clinical characteristics were incom-
plete since such data could not be collected without
consent due to ethical and data protection consider-
ations (see Additional file 1: Table S6).
Acceptability
The mean time to complete the MyPOS (n = 70) was
7 minutes and 19 seconds (SD: 3 minutes 43 seconds).
Median time to complete was 7 minutes (range 1 minute
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pleted the MyPOS without assistance; 66 (17.4%) with
help from a friend or relative; and 35 (9.2%) with help
from a member of staff. Ten out of 27 items had 100%
response rate with no missing data. Seventeen of 27
items had missing data points with the highest rate of
missing data for item about sex (“Over the past week,
have you been worrying about your sex life?”) with 32
(8.4%) missing responses including 31 participants who
responded “prefer not to answer” and 1 who left the
item blank. The percentage of missing item-responses
overall was 0.58%.
Structural validity and identification of subscales
Principal component analysis was carried out to explore
the underlying component (subscale) structure of the
MyPOS. Applying the Kaiser criterion (eigenvalues > 1)
suggested a 7-component solution. The scree plot was
difficult to interpret due to a strong first component,
and suggested either a 2, 3 or 7 component solution.
Velicer’s MAP test suggested a 3-component solution.
These solutions were all tested. As the 3-component so-
lution supports the factors derived from the theoretical
model of QOL in myeloma, this was forced in the SPSS
programme. Table 2 shows the pattern matrix with a
forced three-component solution and after Promax rota-
tion with missing data excluded pairwise. The first com-
ponent (Symptoms & Function) comprised 14 items,
which included an item about diarrhoea that had a fac-
tor loading of below 0.30. This indicates that responses
to the Diarrhoea item did not correlate closely with
other items in the Symptoms & Functions subscale. The
Diarrhoea item also failed to load on any other compo-
nent to >0.30. However, diarrhoea was considered to be
an important clinical symptom, so the item was retained
in the Symptoms & Function subscale on clinical
grounds. The second component (Emotional Response)
comprised 8 items about depression, anxiety, specific
worries and ability to cope with illness and treatment.
The third component (Healthcare Support) comprised 5
items about the accessibility and standard of healthcare
and information received about the illness and treat-
ment. Overall, the three components explained 41.2% of
the variance. The first component (Symptoms & Func-
tion) explained 27.2%; the second component (Emotional
Response) explained 8.0%; and the third component
(Healthcare Support) 6.1%. All items loaded onto the sub-
scale predicted by the model. The principal component
analysis was run again with missing data excluded listwise
and yielded the same factor structure.
Item descriptive statistics
Participants used the full range of response options on
the 5-point scale for all except three items. For the itemabout Vomiting, participants used the lower four re-
sponses only with none using the most severe ‘Over-
whelming’ option. For item about knowledge and skill of
doctors and nurses, participants used the lower four re-
sponses only, with none using the worst option ‘Not at
all’. For the item about care and respect of doctors and
nurses, only the lower 3 options were used with none
using the worst two options ‘Occasionally’ or ‘Not at all’.
Most items showed positive skew. Descriptive statistics
by MyPOS subscale are shown in Table 3.
Reliability
The MyPOS total score showed good internal consistency
with Cronbach’s α = 0.89, which was within the desired
range of 0.7-0.9. Cronbach’s α was also in the desired
range for all MyPOS subscales except the Healthcare Sup-
port scale for which α = 0.64 (Table 3).
Construct validity (known-group comparisons)
All tested hypotheses were confirmed: parametric testing
showed that MyPOS total scores were higher (worse
QOL) in those with newly diagnosed and relapsed or
progressive disease compared to those with stable dis-
ease (F = 11.89, p < 0.001); MyPOS total scores were
higher (worse QOL) in those currently receiving chemo-
therapy compared to those not on treatment (t = 3.42,
p = 0.001); MyPOS Symptoms & Function subscale
scores were higher (worse QOL) in those with worse
ECOG performance status (F = 31.33, p < 0.001). Figure 1
shows theses result using parametric testing. Due to skewed
data these comparisons were also run using equivalent
non-parametric tests with highly similar results.
Convergent and divergent validity
All tested hypotheses were confirmed: MyPOS total
scores correlated negatively with EORTC-QLQ-C30 Global
Health Status/QOL (r =−0.70, p < 0.001); MyPOS Symp-
toms & Function scores correlated negatively with EORTC-
QLQ-C30 Physical Function (r = −0.77, p < 0.001), Role
Function (r =−0.75, p < 0.001), Cognitive Function (r =−0.57,
p < 0.001), Social Function (r = −0.69, p < 0.001) and posi-
tively with MY20 Disease Symptoms (r = 0.65, p < 0.001)
and Side Effects of Treatment (r = 0.74, p < 0.001); MyPOS
Emotional Response scores correlated negatively with
EORTC-QLQ-C30 Emotional Function (r = −0.72, p <
0.001) and MY20 Future Perspectives (r = −0.77, P < 0.001);
and MyPOS Healthcare Support scale did not correlate to
r > 0.50 with any of the EORTC scales or single items.
Discussion
This study reports the development of the MyPOS ques-
tionnaire with input from the literature, clinical staff and
myeloma patients across all disease stages. The MyPOS
is both brief and comprehensive, and pretesting has
Table 3 MyPOS subscale descriptive statistics
Subscale Number of items Possible range Observed range Mean SD Skew αa
MyPOS Symptoms & Function 14 0-56 0-37 13.46 8.25 0.37 0.84
MyPOS Emotional Response 8 0-32 0- 23 6.12 5.30 0.96 0.82
MyPOS Healthcare Support 5 0-20 0-12 1.76 2.43 1.60 0.64
aCronbach’s alpha coefficient of internal reliability.
Table 2 MyPOS principal component pattern matrix with Promax rotation, forced extraction of three components,
missing data excluded pairwise (n = 380)








Pain .62 .08 -.01 .58
Fatigue or lack of energy .80 .01 -.17 .59
Shortness of breath .59 .01 -.17 .40
Diarrhoea .25 .15 -.14 .25
Constipation .45 -.14 .15 .34
Nausea .45 .11 .05 .47
Vomiting .39 -.07 .04 .28
Mouth problems .30 .27 -.19 .36
Poor mobility .88 -.15 -.01 .62
Tingling in the hands and/or feet .47 -.18 .06 .28
Difficulty remembering things .40 .20 -.20 .39
Usual activities without help from others .74 .04 .04 .66
Hobbies and leisure activities .74 .00 .07 .66
Quality time with family and friends .58 -.03 .18 .54
Worry about sex life -.30 .74 -.21 .26
Feeling depressed .17 .53 .06 .59
Anxious or worried about illness or treatment .13 .63 .16 .65
Worry about infections .11 .55 -.04 .46
Worry about physical appearance -.06 .64 .06 .44
Worry about financial situation -.12 .73 .05 .45
Worry that illness will get worse .05 .67 .15 .60
Able to cope with your illness and treatment .33 .39 .14 .63
Doctors or nurses – contact if needed .01 .04 .66 .36
Doctors and nurses – knowledge and skill -.06 -.04 .86 .33
Doctors and nurses – care and respect -.14 -.00 .81 .28
Enough information about illness and treatment -.05 .02 .60 .32
Enough information about the future .22 -.02 .49 .43
Eigenvalue 7.34 2.15 1.64 -
Percentage variance explained 27.2 8.0 6.1 -
Cumulative percentage variance explained 27.2 35.1 41.2 -
aFull item wordings are shown Additional file 1: Table S5.
Figures in bold indicate loadings ≥ .30.
Figures in italics indicate the component/subscale to which each item is assigned.
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Figure 1 Known group comparisons showing MyPOS total score by
phase of disease; MyPOS total score by treatment status; and MyPOS
symptoms & function score by ECOG performance status.
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ment. The cross sectional survey of 380 patients showed
a low time burden and few missing items, and found
that the MyPOS is a reliable and valid tool with the abil-
ity to distinguish between clinically distinct groups, and
good discriminant and divergent validity against sub-
scales of the EORTC-QLQ-C30 and MY20.Cross sectional survey sampling
The use of consecutive enrolment for the psychometric
evaluation ensured that the MyPOS was validated in a
broadly clinically representative group. This is fitting for
a questionnaire designed for clinical use, since validation
should occur in a sample that reflects a questionnaire’s
intended utility. The sample reflected the overall popula-
tion of myeloma patients across all settings, including
inpatients (4.7%), ECOG performance status 3–4 (9.5%),
and those receiving high dose treatment with stem cell
support (1.3%). The final sample of 380 participants was
probably biased towards the more well patients, since 31
(6%) of the 517 patients screened were excluded or de-
clined due to being too unwell, distressed or symptom-
atic. Further validation of the MyPOS specifically in the
inpatient setting may be worthwhile, since this would
probably capture more patients with poor performance
status and receiving high dose treatment with stem cell
support.
In contrast to the MyPOS, the EORTC-QLQ-C30 and
its MY20 module were designed as research tools and
much of their validation has (appropriately) taken place
using myeloma patients recruited into clinical trials
[9,11]. Such samples are much more highly selected and
likely to be medically fitter and suffering from more
acute treatment side effects as compared with clinically
representative groups which will contain a mix of pa-
tients in the later stages of illness for whom different is-
sues may be relevant to QOL. Research tools such as the
EORTC questionnaires may not always, therefore, be
well suited to clinical use [8] and this highlights the im-
portance of tools like the MyPOS that have been devel-
oped specifically for use in clinical settings.
MyPOS Symptoms & Function subscale
The exploratory factor analysis showed that MyPOS
symptom items (e.g. pain; nausea; vomiting) loaded onto
a single subscale with function items (e.g. usual activ-
ities; hobbies and leisure; time with family and friends).
This aligns with the previously reported model of QOL
in myeloma that showed the impact of physical symp-
toms on QOL is dependent on how much they affect ac-
tivities, participation and emotional wellbeing [13]. The
MyPOS asks respondents to consider the impact of
symptoms on ‘activities or concentration’ whereas most
other QOL questionnaires developed or used in mye-
loma ask only about the severity or frequency of symp-
toms and so many not capture all that is important to
QOL [8].
MyPOS Healthcare Support subscale
The MyPOS is the only myeloma-specific QOL question-
naire to contain a subscale dedicated to healthcare factors.
Healthcare factors have been reported as important by
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[13,35-38], and they are useful for clinical teams at both
an individual patient level (e.g. to highlight when a patient
may require more information about their illness), and in
aggregate (e.g. for auditing patient satisfaction across a
service). This makes a strong case for such items to be in-
cluded in myeloma QOL questionnaires, especially where
they are designed with clinical use in mind. As research
tools the EORTC-QLQ-C30 and FACT-MM contain no
healthcare-related items. The EORTC myeloma-specific
module initially included 4 such items as the MY24 [10]
but these were subsequently removed due to ceiling ef-
fects and the module revised to the MY20 [9]. Interest-
ingly, ceiling effects were also seen in 2 out of 5 items in
the MyPOS Healthcare Support subscale, (Knowledge and
skill of doctors and nurses; Care and respect of doctors
and nurses), with no participant using the worst response
options in each case. It was decided to leave these unused
response options in the MyPOS, since their lack of use
may represent a selection bias in favour of patients who
are happy with their clinical team and so happy to partici-
pate in the validation study. It was noted that 28 (5%) of
the 517 patients screened declined to participate but re-
fused to give a reason why, raising the possibility that
within this group are some patients who unwilling to par-
ticipate as they were dissatisfied with their clinical care
and might have used these unused response options.
The Healthcare Support subscale scores had a
Cronbach’s α coefficient of 0.64 which was below the
desired range of 0.7-0.9. This is probably due in part to
the short length of this subscale (5 items). Raising the
number of items in a scale can in itself raise the α coeffi-
cient, even when item correlations remain static [39,40].
High α coefficients can therefore be difficult to achieve in
short scales such as the MyPOS Healthcare Support
subscale.
MyPOS diarrhoea item
This was the only MyPOS item without a factor loading
of ≥0.30 on any subscale. This may be because the scores
for this item were highly skewed, with 73% of respondents
having no diarrhoea and less than 3% with severe or over-
whelming diarrhoea. Severe or overwhelming diarrhoea is
most likely in patients receiving high intensity hospital-
based treatment such as autologous bone marrow trans-
plantation, yet only 4.7% of participants in the cross sec-
tional survey were inpatients. Whilst this low proportion
of inpatients may be clinically representative, this resulted
in problems such as overwhelming diarrhoea being less
well represented the sample. The MyPOS steering
group opted to retain the item on clinical grounds,
since it was considered an important clinical problem
and required for the MyPOS to have utility across dif-
ferent clinical settings.MyPOS sex item
The inclusion of an item about sex is an important
strength of the MyPOS, since it is often omitted from
QOL questionnaires for use in this group [8]. An earlier
qualitative study of QOL in people with myeloma found
that patients felt that sexual function was affected my
myeloma and its treatment, but both patients and staff
find sex difficult to broach in typical clinical consultation
[13]. Examples of reported problems included vaginal
dryness following chemotherapy, and concerns about
sex whilst thrombocytopenic (impaired clotting of the
blood) [13]. Including an item about sex items in the
MyPOS may help empower patients to discuss hid-
den problems and allow the treating physician to
offer appropriate advice, or trigger referral to other
services [41,42].
In contrast to the MyPOS, the most widely used and
validated existing QOL questionnaires in myeloma (the
EORTC-QLQ-C30 and MY20) together contain no item
about sex, although this was considered during the
MY20’s development and highlighted as an area for future
research [10]. The more recently developed FACT-MM
questionnaire does contain the item “I am satisfied with
my sex life”, with a five point Likert scale of responses
[12]. The term ‘sex life’ has been reported as the most
encompassing for different aspects of intimacy [43], and
so the prototype MyPOS item was worded “Have you felt
satisfied with your sex life?”. However, participants in the
cognitive interviews had difficulty with the word satisfac-
tion, reporting that they could only be satisfied with their
sex life after having sex, making the question irrelevant if
no sexual activity had taken place. This problem occurred
despite the lead-in statement: “Please answer this question
regardless of your current amount of sexual activity.” The
wording was therefore amended to “Have you been worry-
ing about your sex life?” It is acknowledged that goes be-
yond rephrasing and changes the meaning of the question.
However, the intended clinical utility of this item is to flag
hidden problems that are difficult for patients and clini-
cians to raise. Asking about worries will still achieve this
end, and was more acceptable to participants in the sec-
ond round of cognitive interviews. The response rate in
the cross sectional survey to the reworded MyPOS sex
item was good for question of this kind, with only 8.4%
missing data.
Methodological limitations
An important limitation of the cognitive interviewing
approach is the reliance on verbal report of cognitive
processes that some people may not be able to articulate
[20]. A larger sample size may also have yielded more re-
finements of the prototype MyPOS.
The use of consecutive enrolment to the cross sec-
tional survey can be seen as both a strength and a
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sentative sample as compared with many other valid-
ation studies in myeloma [8]; the weakness being that
the approach will not have accessed all available patients,
for example those who were unable to attend a clinic ap-
pointment due to feeling unwell at home. The collection
of demographic and clinical details from non-participants
was incomplete due to ethical and data protection issues,
meaning only limited comparisons could be made with
the study sample. Bias in questionnaire responses may also
have resulted from the 26.5% of participants who had help
completing the questionnaire.
The use of a cross sectional design for the psychometric
validation precluded evaluation of test-retest reliability
and responsiveness to change, which require longitudinal
data. True criterion validity could not be assessed in the
absence of an accepted ‘gold standard’ measure of QOL in
this group, so discriminant and divergent validity were
assessed against the EORTC tools as an alternative.
Conclusions
The MyPOS is the first myeloma-specific QOL question-
naire designed specifically for use in the clinical setting.
The MyPOS was developed based on qualitative enquiry
with patients and staff and has been refined with cognitive
assessment. It is a brief, comprehensive and acceptable
tool that is reliable and valid on psychometric testing. The
MyPOS can now be used to support clinical decision mak-
ing in the routine care of myeloma patients, although fur-
ther validation in the inpatient setting may be of value,
alongside longitudinal testing and evaluation with item re-
sponse theory methods.
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